Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ADMA Stock Forecast 2026-2027
$8.81
Current Price
$2.01B
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ADMA Price Targets
+138.4%
To High Target of $21.00
+104.3%
To Median Target of $18.00
+36.2%
To Low Target of $12.00
ADMA Price Momentum
-3.0%
1 Week Change
+4.6%
1 Month Change
-49.9%
1 Year Change
-51.7%
Year-to-Date Change
-56.9%
From 52W High of $20.46
+22.2%
From 52W Low of $7.21
📊 TOP ANALYST CALLS
Did ADMA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ADMA Biologics is one of their latest high-conviction picks.
Latest ADMA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ADMA has a bullish consensus with a median price target of $18.00 (ranging from $12.00 to $21.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $8.81, the median forecast implies a 104.3% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADMA Analyst Ratings
4
Buy
1
Hold
0
Sell
ADMA Price Target Range
Low
$12.00
Average
$18.00
High
$21.00
Current: $8.81
Latest ADMA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADMA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | Gary Nachman | Buy | Maintains | $18.00 |
| May 7, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $20.00 |
| Apr 21, 2026 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Apr 13, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 26, 2026 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| May 8, 2025 | Raymond James | Strong Buy | Maintains | $N/A | |
| Mar 4, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 8, 2024 | Raymond James | Strong Buy | Maintains | $N/A | |
| Oct 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 20, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 9, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jul 9, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jun 20, 2024 | Mizuho | Buy | Maintains | $N/A | |
| May 10, 2024 | Raymond James | Strong Buy | Maintains | $N/A | |
| May 10, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| May 10, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 10, 2024 | Mizuho | Buy | Maintains | $N/A | |
| Mar 26, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Adma Biologics Inc. (ADMA) Competitors
The following stocks are similar to ADMA Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ADMA
ADMA Biologics
mkt cap
2.10B
Adma Biologics Inc. (ADMA) Financial Data
Adma Biologics Inc. has a market capitalization of $2.01B with a P/E ratio of 13.4x. The company generates $509.86M in trailing twelve-month revenue with a 32.4% profit margin.
Revenue growth is +15.9% quarter-over-quarter, while maintaining an operating margin of -123.4% and return on equity of +43.3%.
Valuation Metrics
Market Cap
$2.01B
Enterprise Value
$43.83B
P/E Ratio
13.4x
PEG Ratio
0.2x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
+15.9%
Gross Margin
+70.5%
Operating Margin
-123.4%
Net Margin
+32.4%
EPS Growth
-0.3%
Financial Health
Cash/Price Ratio
+2,738.7%
Current Ratio
7.0x
Debt/Equity
110.7x
ROE
+43.3%
ROA
+22.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Adma Biologics Inc. (ADMA) Business Model
About Adma Biologics Inc.
What They Do
Biopharmaceutical company specializing in plasma-derived therapies.
Business Model
The company operates an integrated business model that includes plasma collection, manufacturing, and commercialization, allowing it to control critical supply chain steps. It generates revenue primarily through its ADMA BioManufacturing segment, producing immunoglobulin and related therapies, as well as from its Plasma Collection Centers which secure source plasma. Additionally, it earns income from selling plasma-derived intermediate fractions and providing laboratory contracting services.
Additional Information
Adma Biologics focuses on treating patients with immune deficiencies and those at risk of infections, primarily in the United States. The company is headquartered in Ramsey, New Jersey, and plays a crucial role in the biotechnology and healthcare sectors by offering specialized plasma-derived therapeutic options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
640
CEO
Mr. Adam S. Grossman
Country
United States
IPO Year
2013
Website
www.admabiologics.comAdma Biologics Inc. (ADMA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.
Jul 13, 2026
By Zacks Equity Research
Tale of the Tape
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
Jul 09, 2026
By Debanjana Dey
Microcap Article
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
Jul 08, 2026
By Ekta Bagri
Analyst Blog
Latest News
Quick Summary
ADMA Biologics faces allegations of inflating ASCENIV revenues due to a channel stuffing scheme, raising concerns for pension funds and asset managers holding positions during this period.
Why It Matters
The alleged channel stuffing at ADMA Biologics significantly inflated revenues, raising concerns about legal liabilities and financial stability, which could impact stock performance and investor trust.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA). Affected investors should contact Pomerantz LLP for more information.
Why It Matters
A class action lawsuit against ADMA Biologics may indicate potential legal and financial risks, affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) who acquired securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit.
Why It Matters
The announcement of a class action lawsuit against ADMA Biologics may lead to increased scrutiny and volatility in its stock price, affecting investor confidence and potential financial performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against ADMA Biologics, Inc. for securities violations. Investors who bought shares from August 9, 2024, to March 25, 2026, should contact Schall Law Firm by August 10, 2026.
Why It Matters
Legal actions can impact stock prices and investor confidence. A class action lawsuit against ADMA Biologics may signal potential financial and reputational risks for the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ADMA Biologics' senior officers are implicated in a securities class action for allegedly concealing financial issues, exposing them to potential liability under federal law.
Why It Matters
The allegations against ADMA Biologics' executives could lead to financial penalties and damage the company's reputation, potentially impacting stock value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Gross Law Firm is notifying ADMA Biologics, Inc. shareholders about a potential lead plaintiff appointment for those who purchased shares during a specified class period.
Why It Matters
ADMA Biologics shareholders may face legal scrutiny, potentially impacting stock value and investor confidence. Legal actions can influence market perception and company stability.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ADMA Stock
What is Adma Biologics Inc.'s (ADMA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Adma Biologics Inc. (ADMA) has a median price target of $18.00. The highest price target is $21.00 and the lowest is $12.00.
Is ADMA stock a good investment in 2027?
According to current analyst ratings, ADMA has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADMA stock?
Wall Street analysts predict ADMA stock could reach $18.00 in the next 12 months. This represents a 104.3% increase from the current price of $8.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adma Biologics Inc.'s business model?
The company operates an integrated business model that includes plasma collection, manufacturing, and commercialization, allowing it to control critical supply chain steps. It generates revenue primarily through its ADMA BioManufacturing segment, producing immunoglobulin and related therapies, as well as from its Plasma Collection Centers which secure source plasma. Additionally, it earns income from selling plasma-derived intermediate fractions and providing laboratory contracting services.
What is the highest forecasted price for ADMA Adma Biologics Inc.?
The highest price target for ADMA is $21.00 from at , which represents a 138.4% increase from the current price of $8.81.
What is the lowest forecasted price for ADMA Adma Biologics Inc.?
The lowest price target for ADMA is $12.00 from at , which represents a 36.2% increase from the current price of $8.81.
What is the overall ADMA consensus from analysts for Adma Biologics Inc.?
The overall analyst consensus for ADMA is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are ADMA stock price projections?
Stock price projections, including those for Adma Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:03 AM UTC